<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:00:59Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8799481" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8799481</identifier>
        <datestamp>2022-02-11</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">101083949</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">22416</journal-id>
              <journal-id journal-id-type="nlm-ta">Pharmacogenomics J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Pharmacogenomics J</journal-id>
              <journal-title-group>
                <journal-title>The pharmacogenomics journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1470-269X</issn>
              <issn pub-type="epub">1473-1150</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8799481</article-id>
              <article-id pub-id-type="pmcid">PMC8799481</article-id>
              <article-id pub-id-type="pmc-uid">8799481</article-id>
              <article-id pub-id-type="pmid">34381173</article-id>
              <article-id pub-id-type="pmid">34381173</article-id>
              <article-id pub-id-type="doi">10.1038/s41397-021-00250-8</article-id>
              <article-id pub-id-type="manuscript">nihpa1730440</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: A randomized trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schacht</surname>
                    <given-names>Joseph P.</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref rid="A1" ref-type="aff">1</xref>
                  <xref rid="A2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoffman</surname>
                    <given-names>Michaela</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref rid="A2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Brian H.</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref rid="A3" ref-type="aff">3</xref>
                  <xref rid="A4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Anton</surname>
                    <given-names>Raymond F.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref rid="A2" ref-type="aff">2</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>Department of Psychiatry, University of Colorado Anschutz Medical Campus</aff>
              <aff id="A2"><label>2</label>Department of Psychiatry &amp; Behavioral Sciences, Medical University of South Carolina</aff>
              <aff id="A3"><label>3</label>FOXO BioScience, Minneapolis, MN</aff>
              <aff id="A4"><label>4</label>Department of Family Medicine and Public Health, University of California, San Diego</aff>
              <author-notes>
                <fn fn-type="con" id="FN1">
                  <p id="P1">Author Contributions</p>
                  <p id="P2">Dr. Schacht conceived the study, conducted the data analysis and interpretation, and drafted the paper. Drs. Hoffman and Chen assisted with data analysis and interpretation. Dr. Anton conceived and designed the study and assisted with data interpretation. All authors revised the paper critically for important intellectual content, approved of the final version, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
                </fn>
                <corresp id="CR1"><bold>Correspondence:</bold> Joseph P. Schacht, Ph.D., Department of Psychiatry, University of Colorado, Anschutz Medical Campus, 13001 East 17<sup>th</sup> Place, Rm. E4311, Aurora, CO 80045, <email>joseph.schacht@cuanschutz.edu</email>, (303) 724-3773</corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>1</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>11</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>11</day>
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <volume>22</volume>
              <issue>1</issue>
              <fpage>1</fpage>
              <lpage>8</lpage>
              <permissions>
                <license>
                  <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: <ext-link ext-link-type="uri" xlink:href="https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms">https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms</ext-link></license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <p id="P3">Polymorphisms in genes associated with opioid signaling and dopamine reuptake and inactivation may moderate naltrexone efficacy in Alcohol Use Disorder (AUD), but the effects of epigenetic modification of these genes on naltrexone response are largely unexplored. This study tested interactions between methylation in the μ-opioid receptor (<italic toggle="yes">OPRM1</italic>), dopamine transporter (<italic toggle="yes">SLC6A3</italic>), and catechol-O-methyltransferase (<italic toggle="yes">COMT</italic>) genes as predictors of naltrexone effects on heavy drinking in a 16-week randomized, placebo-controlled trial among 145 treatment-seeking AUD patients. <italic toggle="yes">OPRM1</italic> methylation interacted with both <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">COMT</italic> methylation to moderate naltrexone efficacy, such that naltrexone-treated individuals with lower methylation of the <italic toggle="yes">OPRM1</italic> promoter and the <italic toggle="yes">SLC6A3</italic> promoter (<italic toggle="yes">p</italic>=.006), <italic toggle="yes">COMT</italic> promoter (<italic toggle="yes">p</italic>=.005), or <italic toggle="yes">SLC6A3</italic> 3’ untranslated region (<italic toggle="yes">p</italic>=.004), relative to placebo and to those with higher <italic toggle="yes">OPRM1</italic> and <italic toggle="yes">SLC6A3</italic> or <italic toggle="yes">COMT</italic> methylation, had significantly fewer heavy drinking days. Epigenetic modification of opioid- and dopamine-related genes may represent a novel pharmacoepigenetic predictor of naltrexone efficacy in AUD.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="S1">
              <title>Introduction</title>
              <p id="P4">The opioid antagonist naltrexone reduces heavy drinking among individuals with Alcohol Use Disorder (AUD) (<xref rid="R1" ref-type="bibr">1</xref>), but is not effective for everyone. Genomic factors might identify subgroups with superior response (<xref rid="R2" ref-type="bibr">2</xref>). Naltrexone is believed to reduce drinking through opioid-mediated effects on alcohol-induced dopamine release (<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>), so genes associated with opioid signaling and dopamine reuptake and inactivation are logical targets. We previously reported epistatic interactions between functional polymorphisms in the μ-opioid receptor (MOR), dopamine transporter (DAT), and catechol-O-methyltransferase (COMT) genes (<italic toggle="yes">OPRM1, SLC6A3</italic>, and <italic toggle="yes">COMT)</italic> that predicted naltrexone response (<xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R7" ref-type="bibr">7</xref>). We focused on single nucleotide polymorphisms (SNPs) in <italic toggle="yes">OPRM1</italic> (rs1799971) and <italic toggle="yes">COMT</italic> (rs4680) and a variable number tandem repeat (VNTR) polymorphism in the <italic toggle="yes">SLC6A3</italic> 3’ untranslated region (rs28363170). Rs1799971 encodes an A-to-G substitution associated with increased MOR binding affinity for β-endorphin (<xref rid="R8" ref-type="bibr">8</xref>) that may also increase MOR affinity for naltrexone (<xref rid="R9" ref-type="bibr">9</xref>), potentiating naltrexone effects. The <italic toggle="yes">SLC6A3</italic> 10-repeat (10R) and <italic toggle="yes">COMT</italic> val alleles have been associated with relatively greater DAT expression (<xref rid="R10" ref-type="bibr">10</xref>) and COMT efficacy, respectively (<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>). Since the DAT and COMT are the primary methods of dopamine inactivation in the striatum (<xref rid="R13" ref-type="bibr">13</xref>) and prefrontal cortex (PFC) (<xref rid="R14" ref-type="bibr">14</xref>), respectively, these alleles likely reduce synaptic dopamine accumulation in these areas.</p>
              <p id="P5">We initially reported that, among non-treatment-seeking AUD individuals, naltrexone, relative to placebo, reduced alcohol self-administration and cue-elicited ventral striatal activation most among <italic toggle="yes">OPRM1</italic> G-allele carriers who were also <italic toggle="yes">SLC6A3</italic> 10R homozygotes (<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>). We subsequently replicated and extended this finding in a randomized controlled trial (RCT) among treatment-seeking AUD patients, in which naltrexone, relative to placebo, most effectively reduced heavy drinking among <italic toggle="yes">OPRM1</italic> G-allele carriers who were also <italic toggle="yes">SLC6A3</italic> 10R or <italic toggle="yes">COMT</italic> val-allele homozygotes (<xref rid="R7" ref-type="bibr">7</xref>). Taken together, these data suggested that a combination of genetically predisposed enhanced MOR function and reduced striatal or cortical synaptic dopamine accumulation was associated with superior naltrexone response.</p>
              <p id="P6">Although germline genetic variation may have utility in predicting naltrexone response, the rs1799971 G allele is relatively infrequent (<xref rid="R15" ref-type="bibr">15</xref>), and epistatic interactions render the genotype combinations associated with superior response rarer still. A more common mechanism by which genomic factors might affect naltrexone response is epigenetic modification. DNA methylation at cytosine residues in CpG (cytosine, followed by guanine) dinucleotides, which are disproportionately clustered into islands in gene promoter regions, inhibits transcription factor binding and recruits histone deacetylase complexes that compact chromatin, thereby decreasing gene expression (<xref rid="R16" ref-type="bibr">16</xref>). Given naltrexone’s neurochemical mechanism of action, <italic toggle="yes">OPRM1, SLC6A3</italic>, and <italic toggle="yes">COMT</italic> methylation could moderate naltrexone response. Methylation of each gene’s promoter has been associated with downstream effects on its expression and the function of the protein it encodes. Greater <italic toggle="yes">OPRM1</italic> promoter methylation in a neural-derived cell line was associated with less MOR expression (<xref rid="R17" ref-type="bibr">17</xref>); greater <italic toggle="yes">SLC6A3</italic> promoter methylation in blood, with less striatal DAT availability (<xref rid="R18" ref-type="bibr">18</xref>); and greater <italic toggle="yes">COMT</italic> promoter methylation in a human cell line, with less <italic toggle="yes">COMT</italic> expression (<xref rid="R19" ref-type="bibr">19</xref>). <italic toggle="yes">OPRM1</italic> and <italic toggle="yes">SLC6A3</italic> methylation have also been associated with AUD and drinking. <italic toggle="yes">OPRM1</italic> (<xref rid="R20" ref-type="bibr">20</xref>) and <italic toggle="yes">SLC6A3</italic> (<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>) promoter methylation were greater among AUD individuals, relative to controls, as was methylation of CpG sites in the <italic toggle="yes">SLC6A3</italic> body (<xref rid="R23" ref-type="bibr">23</xref>). Methylation of several <italic toggle="yes">OPRM1</italic> CpG sites predicted drinking relapse during in a naltrexone RCT, although <italic toggle="yes">OPRM1</italic> methylation did not independently moderate naltrexone effects on drinking (<xref rid="R24" ref-type="bibr">24</xref>). Importantly, <italic toggle="yes">SLC6A3</italic> promoter methylation in blood and substantia nigra correlated highly (<xref rid="R18" ref-type="bibr">18</xref>), as did <italic toggle="yes">COMT</italic> promoter methylation in peripheral leukocytes and a variety of brain regions, including PFC (<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>), suggesting that peripheral <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">COMT</italic> methylation may be biomarkers of neural methylation.</p>
              <p id="P7">Using genomic DNA extracted from peripheral leukocytes from participants in our previous naltrexone RCT (<xref rid="R27" ref-type="bibr">27</xref>), the current study tested whether interactions between <italic toggle="yes">OPRM1, SLC6A3</italic> and <italic toggle="yes">COMT</italic> promoter methylation predicted naltrexone effects on drinking. We hypothesized that methylation of these regions would interact in their effects on naltrexone response in a manner similar to, but not attributable to, the epistatic interactions that predicted response in that RCT, such that naltrexone-treated individuals with lower <italic toggle="yes">OPRM1</italic> methylation (and potentially greater MOR expression) and either lower <italic toggle="yes">SLC6A3</italic> or <italic toggle="yes">COMT</italic> methylation (and potentially greater DAT or COMT expression, engendering less striatal or cortical dopamine accumulation) would demonstrate the least heavy drinking, relative to placebo and to individuals with other combinations of methylation of these regions. The interaction between methylation of CpG sites in the <italic toggle="yes">SLC6A3</italic> VNTR and <italic toggle="yes">OPRM1</italic> promoter methylation was also explored.</p>
            </sec>
            <sec id="S2">
              <title>Methods</title>
              <sec id="S3">
                <title>Overview.</title>
                <p id="P8">Detailed methods for the parent RCT (<ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00920829" ext-link-type="uri">NCT00920829</ext-link>) have been reported previously (<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R27" ref-type="bibr">27</xref>). The Medical University of South Carolina Institutional Review Board approved all procedures, and all participants provided informed consent before participation. Data were collected between June 2009 and December 2015. The study comprised an initial assessment visit, a baseline visit, and nine follow-up visits over a 16-week treatment period. Briefly, community-dwelling participants seeking AUD treatment were assessed for inclusion/exclusion criteria and genotyped for rs1799971. One aim of the parent RCT was to test whether rs1799971 genotype independently predicted naltrexone efficacy, so participants who carried the minor (G) allele were over-selected (<italic toggle="yes">n</italic>=73) to comprise 50% of the 146 evaluable participants (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 1</xref>).</p>
              </sec>
              <sec id="S4">
                <title>Participants.</title>
                <p id="P9">Participants were required to be ages 18–70; report heavy drinking (at least 4/5 standard drinks per day for women/men) on at least 50% of days in the 90 days before assessment; and meet <italic toggle="yes">DSM-IV</italic> (<italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders, revised 4</italic><sup><italic toggle="yes">th</italic></sup>
<italic toggle="yes">edition</italic>) diagnostic criteria for Alcohol Dependence, as assessed by the Structured Clinical Interview for <italic toggle="yes">DSM-IV</italic> (<xref rid="R28" ref-type="bibr">28</xref>). Participants were also required to self-identify as Caucasian or Asian, secondary to low rs1799971 G-allele frequency among individuals of African descent; we previously reported that analysis of population allele frequencies for 50 SNPs included on the methylation assay used here indicated a high degree of correspondence between self-reported and SNP-identified ancestry (<xref rid="R7" ref-type="bibr">7</xref>). Participants who reported cocaine or marijuana use in the 90 days before assessment were included, as long as they did not meet <italic toggle="yes">DSM-IV</italic> criteria for dependence on either substance or any other except nicotine and had a negative urine drug screen upon medication randomization. Exclusion criteria were: current psychotropic medication use other than antidepressants (for which a stable dose for at least one month was required); current <italic toggle="yes">DSM-IV</italic> Axis I diagnosis or suicidal/homicidal ideation; history of significant medical illness; liver enzyme (ALT or AST) levels greater than three times the upper limit of normal; and past-month naltrexone, disulfiram, or acamprosate use. Female participants could not be pregnant or nursing. <xref rid="T1" ref-type="table">Table 1</xref> lists demographic characteristics for the 145 participants included in the analysis (methylation quality-control measures described below led to the exclusion of one participant’s data).</p>
              </sec>
              <sec id="S5">
                <title>Medication, randomization, and assessment.</title>
                <p id="P10">Participants were required to maintain abstinence for at least four days before medication randomization, and were then urn randomized (<xref rid="R29" ref-type="bibr">29</xref>) to receive naltrexone (25 mg for two days, then 50 mg thereafter) or placebo for 16 weeks. Randomization was stratified by rs1799971 genotype, with sex, smoking status (non-smoker vs. smoker, defined as ≥ 10 cigarettes per day), cocaine use, antidepressant use, and AUD family history balanced across medication groups. Study medications were identically over-encapsulated with 100 mg riboflavin (riboflavin-assessed adherence was high and did not vary between medication groups (<xref rid="R27" ref-type="bibr">27</xref>)) and distributed in labeled blister packs. Participants and investigators were blind to genotype and medication assignment. After randomization, participants returned for nine follow-up visits, during which daily drinking since the last visit was assessed with the calendar-based Timeline Follow-back interview (<xref rid="R30" ref-type="bibr">30</xref>). Participants who dropped out after randomization were compensated to return at week 16 to provide missing drinking data. Forty participants ultimately dropped out, at similar rates across medication groups, but full drinking data were available for 89% of participants.</p>
              </sec>
              <sec id="S6">
                <title>DNA collection and genotyping.</title>
                <p id="P11">Genomic DNA was extracted (Gentra Puragene Blood Kit; Qiagen Inc., Valencia, CA) from peripheral blood mononuclear cells collected at the initial assessment visit, stored at −80° C, and used to genotype rs1799971, rs28363170, and rs4680. Details of these assays were previously reported (<xref rid="R7" ref-type="bibr">7</xref>).</p>
              </sec>
              <sec id="S7">
                <title>Methylation assay.</title>
                <p id="P12">An Infinium MethylationEPIC BeadChip (Illumina, San Diego, CA), which assays methylation at 866,895 cytosine residues, 99.7% of which are CpG sites, was used to assess genome-wide DNA methylation. For each subject, 500 ng genomic DNA was bisulfite converted, denatured and amplified, fragmented, resuspended, and hybridized to the BeadChip (eight samples per chip). Each chip included four samples each from naltrexone-and placebo-treated participants, with age (median split) and smoking (smoker vs. non-smoker) evenly distributed within each group of four samples. Age and smoking were selected for balancing because both characteristics affect global DNA methylation (<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref>). During hybridization, the amplified and fragmented DNA annealed to fluorophore-linked probes specific to each CpG site (one for methylated and one for unmethylated sites). Processed BeadChips were then scanned on the Illumina iScan System, which excited each probe’s fluorophores and recorded their fluorescence. Summaries of the probe interrogations yielded average signals for the proportion of alleles that were methylated, vs. unmethylated, at each CpG site.</p>
              </sec>
              <sec id="S8">
                <title>Quality control.</title>
                <p id="P13">RnBeads (<xref rid="R33" ref-type="bibr">33</xref>) was used to examine box plots of the quality of the staining, hybridization, extension, target removal, and bisulfite conversion of the genomic DNA. Distributions and medians of negative control box plots were also examined. Based on these metrics, one participant’s data were judged to be of low quality and excluded, leaving 145 participants for analysis. Probes were subsequently assessed to ensure they were in CpG positions and did not overlap with SNPs with minor allele frequencies &gt;0.01. Data were normalized in R using the preprocessNoob function in the minfi package (<xref rid="R34" ref-type="bibr">34</xref>), which estimates background noise from the out-of-band probes, removes it for each sample separately, and utilizes a subset of the control probes to estimate dye bias.</p>
                <p id="P14">To further assess data quality and examine convergent validity, participants’ age and sex were estimated from the methylation data, and whole-genome methylation differences between smokers (<italic toggle="yes">n</italic>=57) and non-smokers (<italic toggle="yes">n</italic>=88) were tested. First, a well-validated algorithm (<xref rid="R35" ref-type="bibr">35</xref>) was used to predict participants’ ages from the methylation of 30,084 CpG sites; these predictions correlated highly with participants’ self-reported ages (<italic toggle="yes">r</italic>=0.882, <italic toggle="yes">p</italic>&lt;0.001). Second, the Horvath algorithm (<xref rid="R35" ref-type="bibr">35</xref>) and RnBeads also predict sex based on sex chromosome methylation; both predictions exactly matched participants’ self-reported sex. Finally, RnBeads was used to identify differentially methylated CpG sites between smokers and non-smokers, and these sites were compared with the sites whose methylation best discriminated current smokers from non-smokers in a large (<italic toggle="yes">N</italic>=15,907) previous analysis (<xref rid="R32" ref-type="bibr">32</xref>). Four of the five most differentially methylated sites in our data (Illumina probe IDs cg05575921, cg21161138, cg21566642, and cg01940273, none of which were among the <italic toggle="yes">OPRM1</italic>, <italic toggle="yes">SLC6A3</italic>, or <italic toggle="yes">COMT</italic> sites analyzed) were among the top five sites in the previous analysis.</p>
              </sec>
              <sec id="S9">
                <title>Regions analyzed.</title>
                <p id="P15"><xref rid="SD2" ref-type="supplementary-material">Supplemental Figures 2</xref>–<xref rid="SD2" ref-type="supplementary-material">4</xref> show the CpG sites on the BeadChip located in each region analyzed and mean methylation at each site. Not every CpG site in each region was represented on the BeadChip, but all available sites within each region were included. For <italic toggle="yes">OPRM1</italic>, the promoter was defined, consistent with a recent study of <italic toggle="yes">OPRM1</italic> methylation effects on naltrexone response (<xref rid="R24" ref-type="bibr">24</xref>), as the 130 nucleotides upstream and 600 nucleotides downstream of the transcription start site (TSS). For <italic toggle="yes">SLC6A3</italic>, the promoter was defined, consistent with prior studies, as the 1500 nucleotides upstream and 300 nucleotides downstream of the TSS. <italic toggle="yes">COMT</italic> has isoforms that encode both soluble and membrane-bound COMT, each of which has its own promoter (P1 and P2, respectively) (<xref rid="R36" ref-type="bibr">36</xref>). The four CpG sites on the BeadChip in the P1 promoter and eight in the P2 promoter were included. Finally, CpG sites in the <italic toggle="yes">SLC6A3</italic> VNTR region were also analyzed. The BeadChip includes three sites in this region (cg15600751, cg1632193, and cg10838500), but one (cg10838500) occurs only in the 10R allele (<xref rid="R37" ref-type="bibr">37</xref>). Thus, methylation at cg15600751 and cg1632193 was averaged for this analysis.</p>
              </sec>
              <sec id="S10">
                <title>Statistical analysis.</title>
                <p id="P16">Interactions between methylation (averaged across the proportion of methylated alleles at each CpG site in each region) and medication were tested with linear mixed models (SPSS v. 25 MIXED) in which methylation and medication group (naltrexone vs. placebo) were between-subjects factors and time in study (month 1 to 4) was a repeated within-subjects factor. Methylation averages in each region of interest were normally distributed and met assumptions for linear modeling. The dependent variable, as in previous analyses (<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R27" ref-type="bibr">27</xref>), was percent heavy drinking days (PHDD; i.e., the proportion of study days on which women/men drank 4/5 or more standard drinks). Significant methylation by medication interactions indicated that naltrexone effects on PHDD across all study months differed as a function of methylation; significant methylation by medication by time interactions indicated that these effects differed by both methylation and time in study. For each model, the highest-level significant interaction was interpreted by median-splitting methylation levels for each gene and testing, <italic toggle="yes">post hoc</italic>, the simple effect of medication within each combination of methylation level (e.g., high vs. low <italic toggle="yes">OPRM1</italic>, <italic toggle="yes">SLC6A3</italic>, and <italic toggle="yes">COMT</italic> methylation). Effect sizes (Cohen’s <italic toggle="yes">d</italic>) were calculated for groups in which this simple effect was significant.</p>
                <p id="P17">Three primary models were tested (<xref rid="T2" ref-type="table">Table 2</xref>): one included <italic toggle="yes">SLC6A3</italic> promoter methylation, <italic toggle="yes">OPRM1</italic> promoter methylation, medication, time, and all interactions of these factors; and the second and third substituted either <italic toggle="yes">COMT</italic> promoter methylation or <italic toggle="yes">SLC6A3</italic> VNTR methylation for <italic toggle="yes">SLC6A3</italic> promoter methylation. Alpha for these models was Bonferroni-corrected to <italic toggle="yes">p</italic>=0.0167. Alpha for <italic toggle="yes">post hoc</italic> tests, which were conducted only to interpret higher-level interactions, was left at <italic toggle="yes">p</italic>=0.05. Each model used a first-order autoregressive variance-covariance matrix and covaried age. On an exploratory basis, the interaction of every combination of individual CpG sites in each region of interest was also tested to determine whether specific combinations of individual sites interacted with medication group to predict PHDD (<xref rid="SD2" ref-type="supplementary-material">Supplemental Tables 1</xref>–<xref rid="SD2" ref-type="supplementary-material">3</xref>). To test whether methylation effects could be accounted for by the previously reported epistatic interactions (<xref rid="R7" ref-type="bibr">7</xref>), additional models were tested in which <italic toggle="yes">OPRM1</italic> rs1799971 and <italic toggle="yes">SLC6A3</italic> rs28363170 genotypes (dichotomized as G-allele carriers vs. A-allele homozygotes and 9R-allele carriers vs. 10R-allele homozygotes) and their interactions with medication and time were added to the first and third models, and rs1799971 and <italic toggle="yes">COMT</italic> rs4680 (met-allele carriers vs. val-allele homozygotes) genotypes and their interactions were added to the second model.</p>
              </sec>
            </sec>
            <sec id="S11">
              <title>Results</title>
              <sec id="S12">
                <title><italic toggle="yes">SLC6A3</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter.</title>
                <p id="P18">The highest-level significant interaction was between <italic toggle="yes">SLC6A3</italic> promoter methylation, <italic toggle="yes">OPRM1</italic> promoter methylation, medication group, and time (<xref rid="T2" ref-type="table">Table 2</xref>). When <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">OPRM1</italic> methylation were median-split (<xref rid="F1" ref-type="fig">Figure 1</xref>; medians were <italic toggle="yes">SLC6A3</italic>=0.150, <italic toggle="yes">OPRM1</italic>=0.170), naltrexone, relative to placebo, significantly reduced PHDD at month 2 (<italic toggle="yes">F</italic>(1, 217.46)=4.87, mean difference between naltrexone and placebo=16.2% HDD (95% CI=1.7–30.7%), <italic toggle="yes">d</italic>=0.61, <italic toggle="yes">p</italic>=0.028) and month 3 (<italic toggle="yes">F</italic>(1, 232.53)=4.79, mean difference between naltrexone and placebo=16.5% HDD (95% CI=1.7–31.4%), <italic toggle="yes">d</italic>=0.62, <italic toggle="yes">p</italic>=0.030) among individuals with lower methylation of both promoters. The simple effect of medication was not significant at any time point among individuals with any other combination of <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">OPRM1</italic> methylation except those with high <italic toggle="yes">SLC6A3</italic> and low <italic toggle="yes">OPRM1</italic> methylation, among whom this effect was significant at month 3 (<italic toggle="yes">F</italic>(1, 241.14)=5.35, mean difference between naltrexone and placebo=25.7% HDD (95% CI=3.8–47.7%), <italic toggle="yes">d</italic>=0.98, <italic toggle="yes">p</italic>=0.022), as a function of increased PHDD in the placebo group at that point. The <italic toggle="yes">SLC6A3</italic> by <italic toggle="yes">OPRM1</italic> by medication by time interaction remained significant even when rs28363170 genotype, rs1799971 genotype, and their interactions with each other and with medication and time were included in the model, suggesting that the methylation by medication interaction was independent of these other effects.</p>
              </sec>
              <sec id="S13">
                <title><italic toggle="yes">COMT</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter.</title>
                <p id="P19">The highest-level significant interaction was between <italic toggle="yes">COMT</italic> promoter methylation, <italic toggle="yes">OPRM1</italic> promoter methylation, and medication group (<xref rid="T2" ref-type="table">Table 2</xref>). Across all study months, naltrexone, relative to placebo, reduced PHDD more among individuals with lower <italic toggle="yes">COMT</italic> and <italic toggle="yes">OPRM1</italic> methylation. When <italic toggle="yes">COMT</italic> and <italic toggle="yes">OPRM1</italic> methylation were median-split (<xref rid="F2" ref-type="fig">Figure 2</xref>; medians were <italic toggle="yes">COMT</italic>=0.341, <italic toggle="yes">OPRM1</italic>=0.170), naltrexone, relative to placebo, significantly reduced PHDD across all study months only among individuals with lower methylation of both promoters (<italic toggle="yes">F</italic>(1, 154.12)=5.41, mean difference between naltrexone and placebo=19.7% HDD (95% CI=3.0–36.5%), <italic toggle="yes">d</italic>=0.85, <italic toggle="yes">p</italic>=0.021). This interaction remained significant even when rs4680 genotype, rs1799971 genotype, and their interactions with each other and with medication and time were included in the model, suggesting that the methylation by medication interaction was independent of these other effects.</p>
              </sec>
              <sec id="S14">
                <title><italic toggle="yes">SLC6A3</italic> VNTR and <italic toggle="yes">OPRM1</italic> promoter.</title>
                <p id="P20">The highest-level significant interaction was between <italic toggle="yes">SLC6A3</italic> VNTR methylation, <italic toggle="yes">OPRM1</italic> promoter methylation, and medication group (<xref rid="T2" ref-type="table">Table 2</xref>). Across all study months, naltrexone, relative to placebo, reduced PHDD more among individuals with lower <italic toggle="yes">SLC6A3</italic> VNTR and <italic toggle="yes">OPRM1</italic> methylation. When <italic toggle="yes">SLC6A3</italic> VNTR and <italic toggle="yes">OPRM1</italic> promoter methylation were median-split (<xref rid="F3" ref-type="fig">Figure 3</xref>; medians were <italic toggle="yes">SLC6A3</italic>=0.618, <italic toggle="yes">OPRM1</italic>=0.170), naltrexone, relative to placebo, significantly reduced PHDD across all study months only among individuals with lower methylation of both regions (<italic toggle="yes">F</italic>(1, 146.43)=9.93, mean difference between naltrexone and placebo=28.5% HDD (95% CI=10.6–46.3%), <italic toggle="yes">d</italic>=1.25, <italic toggle="yes">p</italic>=0.002). This interaction remained significant even when rs28363170 genotype, rs1799971 genotype, and their interactions with each other and with medication and time were included in the model, again suggesting that the methylation by medication interaction was independent of these other effects.</p>
              </sec>
            </sec>
            <sec id="S15">
              <title>Discussion</title>
              <p id="P21">Taken together, these data suggest that methylation differences in genes underlying opioid signaling and dopamine reuptake and inactivation interact to predict naltrexone treatment effects on heavy drinking among AUD outpatients. Specifically, methylation of the <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">COMT</italic> promoters interacted with <italic toggle="yes">OPRM1</italic> promoter methylation to influence naltrexone efficacy, as did, in an exploratory analysis, methylation of the <italic toggle="yes">SLC6A3</italic> 3’ UTR VNTR region. Effect sizes for naltrexone, relative to placebo, on heavy drinking in the methylation-defined subgroups in which it was most effective were in the medium to large range (<italic toggle="yes">d=</italic>0.61–1.25), greater than the overall small effect of naltrexone on heavy drinking across all AUD individuals (<xref rid="R38" ref-type="bibr">38</xref>). Although preliminary, these findings suggest potentially novel epigenetic predictors of naltrexone response.</p>
              <p id="P22">Epigenetic changes in genes that may underlie naltrexone’s effects on dopamine signaling interacted with <italic toggle="yes">OPRM1</italic> methylation to predict its effects on drinking. Alcohol acutely elicits striatal dopamine release (<xref rid="R39" ref-type="bibr">39</xref>) and naltrexone blocks this phenomenon (<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>). DAT and COMT are the primary methods of dopamine inactivation in the striatum (<xref rid="R13" ref-type="bibr">13</xref>) and PFC (<xref rid="R14" ref-type="bibr">14</xref>), respectively. <italic toggle="yes">SLC6A3</italic> rs28363170 and <italic toggle="yes">OPRM1</italic> rs1799971 variation have previously been reported to interact in their effects on acute response to alcohol, such that individuals carrying the gain-of-function alleles of each polymorphism (i.e., 10R and G) displayed lower hedonic response (<xref rid="R40" ref-type="bibr">40</xref>). Since lower <italic toggle="yes">OPRM1, SLC6A3,</italic> and <italic toggle="yes">COMT</italic> promoter methylation have been associated with relatively increased expression of these genes (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R26" ref-type="bibr">26</xref>), naltrexone might more effectively reduce heavy drinking among individuals with lower methylation of these regions because this pattern of methylation predisposes greater MOR availability and more effective synaptic dopamine clearance after alcohol-induced dopamine release. With respect to methylation of the <italic toggle="yes">SLC6A3</italic> 3’ UTR VNTR, CpG methylation outside of gene promoters can also regulate gene expression (<xref rid="R41" ref-type="bibr">41</xref>), and 3’ UTRs contain regulatory regions that can influence a variety of posttranscriptional modifications that affect gene expression (<xref rid="R42" ref-type="bibr">42</xref>). The <italic toggle="yes">SLC6A3</italic> VNTR modulates <italic toggle="yes">SLC6A3</italic> expression (<xref rid="R43" ref-type="bibr">43</xref>), potentially via transcription factor binding in this region (<xref rid="R44" ref-type="bibr">44</xref>). Thus, greater <italic toggle="yes">SLC6A3</italic> VNTR methylation could modulate transcription or posttranscriptional functions that affect <italic toggle="yes">SLC6A3</italic> expression. We previously reported epistatic genetic effects on naltrexone efficacy in this sample, but the significance of the methylation effects persisted when these genetic effects were included in the models, suggesting that, even after accounting for variance attributable to epistatic effects, interactions between <italic toggle="yes">OPRM1</italic> methylation and <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">COMT</italic> methylation independently predicted naltrexone effects.</p>
              <p id="P23">Consistent with a secondary analysis of another AUD naltrexone RCT (<xref rid="R24" ref-type="bibr">24</xref>) and a meta-analysis of <italic toggle="yes">OPRM1</italic> rs1799971 pharmacogenetic effects (<xref rid="R45" ref-type="bibr">45</xref>), <italic toggle="yes">OPRM1</italic> methylation did not independently moderate naltrexone response (i.e., <italic toggle="yes">OPRM1</italic> by medication interactions were significant only in the context of higher-level interactions with <italic toggle="yes">SLC6A3</italic> or <italic toggle="yes">COMT</italic> methylation). The rs1799971 meta-analysis included the primary analysis of the data used in the current study (<xref rid="R27" ref-type="bibr">27</xref>), which also did not support this pharmacogenetic effect. Collectively, these findings suggest that, despite the fact that naltrexone directly antagonizes the MOR, the effects of genetic or epigenetic alteration of <italic toggle="yes">OPRM1</italic> alone are not sufficiently large to consistently affect naltrexone response.</p>
              <p id="P24">Several factors limit interpretation of these findings. First, brain-based interpretations of these data rely upon extrapolation of methylation levels in peripheral leukocytes, from which DNA was extracted, to neural tissue; methylation levels vary between cell types (<xref rid="R46" ref-type="bibr">46</xref>), and this extrapolation may not be valid. However, peripheral <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">COMT</italic> promoter methylation has been reported to correlate highly with methylation of these regions in a variety of brain regions, including the substantia nigra and PFC (<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R25" ref-type="bibr">25</xref>). Second, the use of a whole-genome methylation chip afforded the ability to analyze multiple regions of interest without pyrosequencing each region individually, at the cost of including every CpG site within each region. Illumina chose the CpG sites on the BeadChip to maximize coverage of promoter and enhancer regions, and CpG sites near each other generally share a large amount of variance in their methylation levels, so the sites included in these analyses are a reasonable proxy for the methylation of the larger regions in which they are located. Nevertheless, inclusion of CpG sites that affect the binding of specific transcription factors could have altered results; future studies should further explore this possibility. Although this paper employed a hypothesis-driven, candidate gene approach, a genome-wide pharmacoepigenetic analysis would also be valuable, as the methylation status of genes involved in other AUD-related pathways (e.g., alcohol metabolism) or naltrexone pharmacokinetics/pharmacodynamics might also influence naltrexone efficacy. Third, blood samples were collected only at baseline; the lack of a post-treatment sample precluded testing whether naltrexone or drinking status <italic toggle="yes">altered</italic> methylation of the genetic regions of interest. Finally, although the study was powered to detect an interaction between <italic toggle="yes">OPRM1</italic> rs1799971 genotype and medication group, sample size limits interpretation of gene-by-gene methylation interactions.</p>
              <p id="P25">In conclusion, this study found that AUD individuals with less methylation of the <italic toggle="yes">OPRM1</italic> and <italic toggle="yes">SLC6A3</italic> or <italic toggle="yes">COMT</italic> promoters, or the <italic toggle="yes">SLC6A3</italic> 3’UTR VNTR, were more likely to benefit from naltrexone, relative to placebo, than individuals with other combinations of methylation in these regions. These data should be tested for replication in other naltrexone RCT datasets, and, if replicated, could support the utility of a novel pharmacoepigenetic approach to naltrexone treatment in AUD.</p>
            </sec>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <label>Supplemental Figure 1</label>
                <media xlink:href="NIHMS1730440-supplement-Supplemental_Figure_1.pdf" id="d64e1013" position="anchor"/>
              </supplementary-material>
              <supplementary-material id="SD2" position="float" content-type="local-data">
                <label>Supplemental Figures 2-4 and Supplemental Tables 1-3</label>
                <media xlink:href="NIHMS1730440-supplement-Supplemental_Figures_2-4_and_Supplemental_Tables_1-3.docx" id="d64e1016" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S16">
              <title>Acknowledgements</title>
              <p id="P26">We gratefully acknowledge Robert Wilson, Ph.D., W. Bailey Glen, Ph.D., and E. Starr Hazard, Ph.D. for their assistance with conducting the methylation assays; Patricia Latham, Ph.D., R.N., Sarah Book, M.D., and Scott Stewart, M. D., for medical management of participants; Konstantin Voronin, M.D., Ph.D., Mark Ghent, B. A., and Melissa Michel, M. A., for assistance with participant recruitment and assessment; Patrick K. Randall, Ph.D., for study data management and initial statistical support; and Yeong-bin Im, M. S., for performing the DNA extraction and genotyping assays.</p>
              <sec id="S18">
                <title>Funding and Disclosures</title>
                <p id="P27">This research was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (R01 AA017633, PI: Anton) and the Medical University of South Carolina Center for Genomic Medicine (PI: Schacht). Additional funding was provided by a generous gift from Robert and Karen Sywolski. Dr. Schacht reports that, in the past three years, he has consulted for and received grant funding from Laboratorio Farmaceutico CT. Dr. Chen is an employee of FOXO BioScience. Dr. Anton reports that, in the past three years, he has received grant funding from Laboratorio Farmaceutico CT and consulted for Allergan, Alkermes, Dicerna, Insys, and Life Epigenetics (FOXO BioScience). He is the Chair of the Alcohol Clinical Trials Initiative (ACTIVE), which is conducted under the auspices of the American Society for Clinical Psychopharmacology and funded (in the past 3 years) in part by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. Dr. Hoffman reports no biomedical financial interests or potential conflicts of interest.</p>
              </sec>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><name><surname>Jonas</surname><given-names>DE</given-names></name>, <name><surname>Amick</surname><given-names>HR</given-names></name>, <name><surname>Feltner</surname><given-names>C</given-names></name>, <name><surname>Bobashev</surname><given-names>G</given-names></name>, <name><surname>Thomas</surname><given-names>K</given-names></name>, <name><surname>Wines</surname><given-names>R</given-names></name>, <etal/><article-title>Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>(<issue>18</issue>):<fpage>1889</fpage>–<lpage>900</lpage>.<pub-id pub-id-type="pmid">24825644</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>JD</given-names></name>, <name><surname>Comer</surname><given-names>SD</given-names></name>, <name><surname>Kranzler</surname><given-names>HR</given-names></name>. <article-title>The pharmacogenetics of alcohol use disorder</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2015</year>;<volume>39</volume>(<issue>3</issue>):<fpage>391</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="pmid">25703505</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><name><surname>Gonzales</surname><given-names>RA</given-names></name>, <name><surname>Weiss</surname><given-names>F</given-names></name>. <article-title>Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens</article-title>. <source>J Neurosci</source>. <year>1998</year>;<volume>18</volume>(<issue>24</issue>):<fpage>10663</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">9852601</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><name><surname>Benjamin</surname><given-names>D</given-names></name>, <name><surname>Grant</surname><given-names>ER</given-names></name>, <name><surname>Pohorecky</surname><given-names>LA</given-names></name>. <article-title>Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats</article-title>. <source>Brain Research</source>. <year>1993</year>;<volume>621</volume>(<issue>1</issue>):<fpage>137</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">7693299</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><name><surname>Schacht</surname><given-names>JP</given-names></name>, <name><surname>Anton</surname><given-names>RF</given-names></name>, <name><surname>Voronin</surname><given-names>KE</given-names></name>, <name><surname>Randall</surname><given-names>PK</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Henderson</surname><given-names>S</given-names></name>, <etal/><article-title>Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues</article-title>. <source>Neuropsychopharmacology</source>. <year>2013</year>;<volume>38</volume>(<issue>3</issue>):<fpage>414</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">23032071</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><name><surname>Anton</surname><given-names>RF</given-names></name>, <name><surname>Voronin</surname><given-names>KK</given-names></name>, <name><surname>Randall</surname><given-names>PK</given-names></name>, <name><surname>Myrick</surname><given-names>H</given-names></name>, <name><surname>Tiffany</surname><given-names>A</given-names></name>. <article-title>Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2012</year>;<volume>36</volume>(<issue>11</issue>):<fpage>2000</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">22551036</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><name><surname>Anton</surname><given-names>RF</given-names></name>, <name><surname>Voronin</surname><given-names>KE</given-names></name>, <name><surname>Book</surname><given-names>SW</given-names></name>, <name><surname>Latham</surname><given-names>PK</given-names></name>, <name><surname>Randall</surname><given-names>PK</given-names></name>, <name><surname>Glen</surname><given-names>WB</given-names></name>, <etal/><article-title>Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><name><surname>Bond</surname><given-names>C</given-names></name>, <name><surname>LaForge</surname><given-names>KS</given-names></name>, <name><surname>Tian</surname><given-names>M</given-names></name>, <name><surname>Melia</surname><given-names>D</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Borg</surname><given-names>L</given-names></name>, <etal/><article-title>Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1998</year>;<volume>95</volume>(<issue>16</issue>):<fpage>9608</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">9689128</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><name><surname>Weerts</surname><given-names>EM</given-names></name>, <name><surname>McCaul</surname><given-names>ME</given-names></name>, <name><surname>Kuwabara</surname><given-names>H</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Dannals</surname><given-names>RF</given-names></name>, <etal/><article-title>Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects</article-title>. <source>Int J Neuropsychopharmacol</source>. <year>2013</year>;<volume>16</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">22397905</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><name><surname>Heinz</surname><given-names>A</given-names></name>, <name><surname>Goldman</surname><given-names>D</given-names></name>, <name><surname>Jones</surname><given-names>DW</given-names></name>, <name><surname>Palmour</surname><given-names>R</given-names></name>, <name><surname>Hommer</surname><given-names>D</given-names></name>, <name><surname>Gorey</surname><given-names>JG</given-names></name>, <etal/><article-title>Genotype influences in vivo dopamine transporter availability in human striatum</article-title>. <source>Neuropsychopharmacology</source>. <year>2000</year>;<volume>22</volume>(<issue>2</issue>):<fpage>133</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">10649826</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Lipska</surname><given-names>BK</given-names></name>, <name><surname>Halim</surname><given-names>N</given-names></name>, <name><surname>Ma</surname><given-names>QD</given-names></name>, <name><surname>Matsumoto</surname><given-names>M</given-names></name>, <name><surname>Melhem</surname><given-names>S</given-names></name>, <etal/><article-title>Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain</article-title>. <source>Am J Hum Genet</source>. <year>2004</year>;<volume>75</volume>(<issue>5</issue>):<fpage>807</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15457404</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><name><surname>Lachman</surname><given-names>HM</given-names></name>, <name><surname>Papolos</surname><given-names>DF</given-names></name>, <name><surname>Saito</surname><given-names>T</given-names></name>, <name><surname>Yu</surname><given-names>YM</given-names></name>, <name><surname>Szumlanski</surname><given-names>CL</given-names></name>, <name><surname>Weinshilboum</surname><given-names>RM</given-names></name>. <article-title>Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders</article-title>. <source>Pharmacogenetics</source>. <year>1996</year>;<volume>6</volume>(<issue>3</issue>):<fpage>243</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">8807664</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><name><surname>Ciliax</surname><given-names>BJ</given-names></name>, <name><surname>Drash</surname><given-names>GW</given-names></name>, <name><surname>Staley</surname><given-names>JK</given-names></name>, <name><surname>Haber</surname><given-names>S</given-names></name>, <name><surname>Mobley</surname><given-names>CJ</given-names></name>, <name><surname>Miller</surname><given-names>GW</given-names></name>, <etal/><article-title>Immunocytochemical localization of the dopamine transporter in human brain</article-title>. <source>The Journal of Comparative Neurology</source>. <year>1999</year>;<volume>409</volume>(<issue>1</issue>):<fpage>38</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">10363710</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><name><surname>Matsumoto</surname><given-names>M</given-names></name>, <name><surname>Weickert</surname><given-names>CS</given-names></name>, <name><surname>Akil</surname><given-names>M</given-names></name>, <name><surname>Lipska</surname><given-names>BK</given-names></name>, <name><surname>Hyde</surname><given-names>TM</given-names></name>, <name><surname>Herman</surname><given-names>MM</given-names></name>, <etal/><article-title>Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function</article-title>. <source>Neuroscience</source>. <year>2003</year>;<volume>116</volume>(<issue>1</issue>):<fpage>127</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">12535946</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><name><surname>Gelernter</surname><given-names>J</given-names></name>, <name><surname>Kranzler</surname><given-names>H</given-names></name>, <name><surname>Cubells</surname><given-names>J</given-names></name>. <article-title>Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects</article-title>. <source>Mol Psychiatry</source>. <year>1999</year>;<volume>4</volume>(<issue>5</issue>):<fpage>476</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">10523821</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PA</given-names></name>. <article-title>Functions of DNA methylation: islands, start sites, gene bodies and beyond</article-title>. <source>Nat Rev Genet</source>. <year>2012</year>;<volume>13</volume>(<issue>7</issue>):<fpage>484</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">22641018</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><name><surname>Andria</surname><given-names>ML</given-names></name>, <name><surname>Simon</surname><given-names>EJ</given-names></name>. <article-title>Localization of promoter elements in the human mu-opioid receptor gene and regulation by DNA methylation</article-title>. <source>Brain Res Mol Brain Res</source>. <year>1999</year>;<volume>70</volume>(<issue>1</issue>):<fpage>54</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">10381543</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><name><surname>Wiers</surname><given-names>CE</given-names></name>, <name><surname>Lohoff</surname><given-names>FW</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Muench</surname><given-names>C</given-names></name>, <name><surname>Freeman</surname><given-names>C</given-names></name>, <name><surname>Zehra</surname><given-names>A</given-names></name>, <etal/><article-title>Methylation of the dopamine transporter gene in blood is associated with striatal dopamine transporter availability in ADHD: A preliminary study</article-title>. <source>Eur J Neurosci</source>. <year>2018</year>;<volume>48</volume>(<issue>3</issue>):<fpage>1884</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">30033547</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><name><surname>Swift-Scanlan</surname><given-names>T</given-names></name>, <name><surname>Smith</surname><given-names>CT</given-names></name>, <name><surname>Bardowell</surname><given-names>SA</given-names></name>, <name><surname>Boettiger</surname><given-names>CA</given-names></name>. <article-title>Comprehensive interrogation of CpG island methylation in the gene encoding COMT, a key estrogen and catecholamine regulator</article-title>. <source>BMC Med Genomics</source>. <year>2014</year>;<volume>7</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">24460628</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Herman</surname><given-names>AI</given-names></name>, <name><surname>Kranzler</surname><given-names>HR</given-names></name>, <name><surname>Anton</surname><given-names>RF</given-names></name>, <name><surname>Simen</surname><given-names>AA</given-names></name>, <name><surname>Gelernter</surname><given-names>J</given-names></name>. <article-title>Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence</article-title>. <source>J Hum Genet</source>. <year>2012</year>;<volume>57</volume>(<issue>10</issue>):<fpage>670</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">22914673</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><name><surname>Hillemacher</surname><given-names>T</given-names></name>, <name><surname>Frieling</surname><given-names>H</given-names></name>, <name><surname>Hartl</surname><given-names>T</given-names></name>, <name><surname>Wilhelm</surname><given-names>J</given-names></name>, <name><surname>Kornhuber</surname><given-names>J</given-names></name>, <name><surname>Bleich</surname><given-names>S</given-names></name>. <article-title>Promoter specific methylation of the dopamine transporter gene is altered in alcohol dependence and associated with craving</article-title>. <source>J Psychiatr Res</source>. <year>2009</year>;<volume>43</volume>(<issue>4</issue>):<fpage>388</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">18504048</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><name><surname>Wiers</surname><given-names>CE</given-names></name>, <name><surname>Shumay</surname><given-names>E</given-names></name>, <name><surname>Volkow</surname><given-names>ND</given-names></name>, <name><surname>Frieling</surname><given-names>H</given-names></name>, <name><surname>Kotsiari</surname><given-names>A</given-names></name>, <name><surname>Lindenmeyer</surname><given-names>J</given-names></name>, <etal/><article-title>Effects of depressive symptoms and peripheral DAT methylation on neural reactivity to alcohol cues in alcoholism</article-title>. <source>Translational psychiatry</source>. <year>2015</year>;<volume>5</volume>:<fpage>e648</fpage>.<pub-id pub-id-type="pmid">26418276</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><name><surname>Ruggeri</surname><given-names>B</given-names></name>, <name><surname>Nymberg</surname><given-names>C</given-names></name>, <name><surname>Vuoksimaa</surname><given-names>E</given-names></name>, <name><surname>Lourdusamy</surname><given-names>A</given-names></name>, <name><surname>Wong</surname><given-names>CP</given-names></name>, <name><surname>Carvalho</surname><given-names>FM</given-names></name>, <etal/><article-title>Association of Protein Phosphatase PPM1G With Alcohol Use Disorder and Brain Activity During Behavioral Control in a Genome-Wide Methylation Analysis</article-title>. <source>Am J Psychiatry</source>. <year>2015</year>;<volume>172</volume>(<issue>6</issue>):<fpage>543</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">25982659</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>Y</given-names></name>, <name><surname>Kranzler</surname><given-names>HR</given-names></name>, <name><surname>Farrer</surname><given-names>LA</given-names></name>, <name><surname>Xu</surname><given-names>H</given-names></name>, <name><surname>Henderson</surname><given-names>DC</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>. <article-title>An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence</article-title>. <source>Pharmacogenomics J</source>. <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><name><surname>Ursini</surname><given-names>G</given-names></name>, <name><surname>Bollati</surname><given-names>V</given-names></name>, <name><surname>Fazio</surname><given-names>L</given-names></name>, <name><surname>Porcelli</surname><given-names>A</given-names></name>, <name><surname>Iacovelli</surname><given-names>L</given-names></name>, <name><surname>Catalani</surname><given-names>A</given-names></name>, <etal/><article-title>Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity</article-title>. <source>J Neurosci</source>. <year>2011</year>;<volume>31</volume>(<issue>18</issue>):<fpage>6692</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">21543598</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><name><surname>Murphy</surname><given-names>BC</given-names></name>, <name><surname>O’Reilly</surname><given-names>RL</given-names></name>, <name><surname>Singh</surname><given-names>SM</given-names></name>. <article-title>Site-specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source>. <year>2005</year>;<volume>133B</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">15635661</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><name><surname>Schacht</surname><given-names>JP</given-names></name>, <name><surname>Randall</surname><given-names>PK</given-names></name>, <name><surname>Latham</surname><given-names>PK</given-names></name>, <name><surname>Voronin</surname><given-names>KE</given-names></name>, <name><surname>Book</surname><given-names>SW</given-names></name>, <name><surname>Myrick</surname><given-names>H</given-names></name>, <etal/><article-title>Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status</article-title>. <source>Neuropsychopharmacology</source>. <year>2017</year>;<volume>42</volume>(<issue>13</issue>):<fpage>2640</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">28409564</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="book"><name><surname>First</surname><given-names>MB</given-names></name>, <name><surname>Spitzer</surname><given-names>RL</given-names></name>, <name><surname>Gibbon</surname><given-names>M</given-names></name>, <name><surname>Williams</surname><given-names>JBW</given-names></name>. <source>Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Biometrics Research, New York State Psychiatric Institute</publisher-name>; <year>2002</year>.</mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><name><surname>Stout</surname><given-names>RL</given-names></name>, <name><surname>Wirtz</surname><given-names>PW</given-names></name>, <name><surname>Carbonari</surname><given-names>JP</given-names></name>, <name><surname>Del Boca</surname><given-names>FK</given-names></name>. <article-title>Ensuring balanced distribution of prognostic factors in treatment outcome research</article-title>. <source>J Stud Alcohol Suppl</source>. <year>1994</year>;<volume>12</volume>:<fpage>70</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">7723001</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="book"><name><surname>Sobell</surname><given-names>LC</given-names></name>, <name><surname>Sobell</surname><given-names>MB</given-names></name>. <part-title>Timeline follow-back: A technique for assessing self-reported alcohol consumption</part-title>. In: <name><surname>Allen</surname><given-names>JP</given-names></name>, <name><surname>Litten</surname><given-names>RZ</given-names></name>, editors. <source>Measuring alcohol consumption: Psychosocial and biochemical methods</source>. <publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana Press</publisher-name>; <year>1992</year>. p. <fpage>41</fpage>–<lpage>72</lpage>.</mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><name><surname>Horvath</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Langfelder</surname><given-names>P</given-names></name>, <name><surname>Kahn</surname><given-names>RS</given-names></name>, <name><surname>Boks</surname><given-names>MP</given-names></name>, <name><surname>van Eijk</surname><given-names>K</given-names></name>, <etal/><article-title>Aging effects on DNA methylation modules in human brain and blood tissue</article-title>. <source>Genome Biol</source>. <year>2012</year>;<volume>13</volume>(<issue>10</issue>):<fpage>R97</fpage>.<pub-id pub-id-type="pmid">23034122</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><name><surname>Joehanes</surname><given-names>R</given-names></name>, <name><surname>Just</surname><given-names>AC</given-names></name>, <name><surname>Marioni</surname><given-names>RE</given-names></name>, <name><surname>Pilling</surname><given-names>LC</given-names></name>, <name><surname>Reynolds</surname><given-names>LM</given-names></name>, <name><surname>Mandaviya</surname><given-names>PR</given-names></name>, <etal/><article-title>Epigenetic Signatures of Cigarette Smoking</article-title>. <source>Circ Cardiovasc Genet</source>. <year>2016</year>;<volume>9</volume>(<issue>5</issue>):<fpage>436</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">27651444</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><name><surname>Assenov</surname><given-names>Y</given-names></name>, <name><surname>Muller</surname><given-names>F</given-names></name>, <name><surname>Lutsik</surname><given-names>P</given-names></name>, <name><surname>Walter</surname><given-names>J</given-names></name>, <name><surname>Lengauer</surname><given-names>T</given-names></name>, <name><surname>Bock</surname><given-names>C</given-names></name>. <article-title>Comprehensive analysis of DNA methylation data with RnBeads</article-title>. <source>Nat Methods</source>. <year>2014</year>;<volume>11</volume>(<issue>11</issue>):<fpage>1138</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">25262207</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><name><surname>Aryee</surname><given-names>MJ</given-names></name>, <name><surname>Jaffe</surname><given-names>AE</given-names></name>, <name><surname>Corrada-Bravo</surname><given-names>H</given-names></name>, <name><surname>Ladd-Acosta</surname><given-names>C</given-names></name>, <name><surname>Feinberg</surname><given-names>AP</given-names></name>, <name><surname>Hansen</surname><given-names>KD</given-names></name>, <etal/><article-title>Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1363</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">24478339</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><name><surname>Horvath</surname><given-names>S</given-names></name><article-title>DNA methylation age of human tissues and cell types</article-title>. <source>Genome Biol</source>. <year>2013</year>;<volume>14</volume>(<issue>10</issue>):<fpage>R115</fpage>.<pub-id pub-id-type="pmid">24138928</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><name><surname>Tenhunen</surname><given-names>J</given-names></name>, <name><surname>Salminen</surname><given-names>M</given-names></name>, <name><surname>Lundstrom</surname><given-names>K</given-names></name>, <name><surname>Kiviluoto</surname><given-names>T</given-names></name>, <name><surname>Savolainen</surname><given-names>R</given-names></name>, <name><surname>Ulmanen</surname><given-names>I</given-names></name>. <article-title>Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters</article-title>. <source>Eur J Biochem</source>. <year>1994</year>;<volume>223</volume>(<issue>3</issue>):<fpage>1049</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">8055944</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><name><surname>Fuke</surname><given-names>S</given-names></name>, <name><surname>Suo</surname><given-names>S</given-names></name>, <name><surname>Takahashi</surname><given-names>N</given-names></name>, <name><surname>Koike</surname><given-names>H</given-names></name>, <name><surname>Sasagawa</surname><given-names>N</given-names></name>, <name><surname>Ishiura</surname><given-names>S</given-names></name>. <article-title>The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression</article-title>. <source>Pharmacogenom J</source>. <year>2001</year>;<volume>1</volume>(<issue>2</issue>):<fpage>152</fpage>–<lpage>6</lpage>.</mixed-citation>
              </ref>
              <ref id="R38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><name><surname>Maisel</surname><given-names>NC</given-names></name>, <name><surname>Blodgett</surname><given-names>JC</given-names></name>, <name><surname>Wilbourne</surname><given-names>PL</given-names></name>, <name><surname>Humphreys</surname><given-names>K</given-names></name>, <name><surname>Finney</surname><given-names>JW</given-names></name>. <article-title>Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?</article-title><source>Addiction</source>. <year>2013</year>;<volume>108</volume>(<issue>2</issue>):<fpage>275</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">23075288</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><name><surname>Boileau</surname><given-names>I</given-names></name>, <name><surname>Assaad</surname><given-names>J-M</given-names></name>, <name><surname>Pihl</surname><given-names>RO</given-names></name>, <name><surname>Benkelfat</surname><given-names>C</given-names></name>, <name><surname>Leyton</surname><given-names>M</given-names></name>, <name><surname>Diksic</surname><given-names>M</given-names></name>, <etal/><article-title>Alcohol promotes dopamine release in the human nucleus accumbens</article-title>. <source>Synapse (New York, NY)</source>. <year>2003</year>;<volume>49</volume>(<issue>4</issue>):<fpage>226</fpage>–<lpage>31</lpage>.</mixed-citation>
              </ref>
              <ref id="R40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><name><surname>Weerts</surname><given-names>EM</given-names></name>, <name><surname>Wand</surname><given-names>GS</given-names></name>, <name><surname>Maher</surname><given-names>B</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Stephens</surname><given-names>MA</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <etal/><article-title>Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2017</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1093</fpage>–<lpage>104</lpage>.<pub-id pub-id-type="pmid">28376280</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><name><surname>Maunakea</surname><given-names>AK</given-names></name>, <name><surname>Nagarajan</surname><given-names>RP</given-names></name>, <name><surname>Bilenky</surname><given-names>M</given-names></name>, <name><surname>Ballinger</surname><given-names>TJ</given-names></name>, <name><surname>D’Souza</surname><given-names>C</given-names></name>, <name><surname>Fouse</surname><given-names>SD</given-names></name>, <etal/><article-title>Conserved role of intragenic DNA methylation in regulating alternative promoters</article-title>. <source>Nature</source>. <year>2010</year>;<volume>466</volume>(<issue>7303</issue>):<fpage>253</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">20613842</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>LW</given-names></name>, <name><surname>Fletcher</surname><given-names>S</given-names></name>, <name><surname>Wilton</surname><given-names>SD</given-names></name>. <article-title>Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements</article-title>. <source>Cell Mol Life Sci</source>. <year>2012</year>;<volume>69</volume>(<issue>21</issue>):<fpage>3613</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">22538991</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><name><surname>Michelhaugh</surname><given-names>SK</given-names></name>, <name><surname>Fiskerstrand</surname><given-names>C</given-names></name>, <name><surname>Lovejoy</surname><given-names>E</given-names></name>, <name><surname>Bannon</surname><given-names>MJ</given-names></name>, <name><surname>Quinn</surname><given-names>JP</given-names></name>. <article-title>The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons</article-title>. <source>J Neurochem</source>. <year>2001</year>;<volume>79</volume>(<issue>5</issue>):<fpage>1033</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">11739616</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><name><surname>Fuke</surname><given-names>S</given-names></name>, <name><surname>Sasagawa</surname><given-names>N</given-names></name>, <name><surname>Ishiura</surname><given-names>S</given-names></name>. <article-title>Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3’ non-coding polymorphic region of the human dopamine transporter (DAT1) gene</article-title>. <source>J Biochem</source>. <year>2005</year>;<volume>137</volume>(<issue>2</issue>):<fpage>205</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">15749835</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><name><surname>Hartwell</surname><given-names>EE</given-names></name>, <name><surname>Feinn</surname><given-names>R</given-names></name>, <name><surname>Morris</surname><given-names>PE</given-names></name>, <name><surname>Gelernter</surname><given-names>J</given-names></name>, <name><surname>Krystal</surname><given-names>J</given-names></name>, <name><surname>Arias</surname><given-names>AJ</given-names></name>, <etal/><article-title>Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder</article-title>. <source>Addiction</source>. <year>2020</year>;<volume>115</volume>(<issue>8</issue>):<fpage>1426</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">31961981</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><name><surname>Illingworth</surname><given-names>R</given-names></name>, <name><surname>Kerr</surname><given-names>A</given-names></name>, <name><surname>Desousa</surname><given-names>D</given-names></name>, <name><surname>Jorgensen</surname><given-names>H</given-names></name>, <name><surname>Ellis</surname><given-names>P</given-names></name>, <name><surname>Stalker</surname><given-names>J</given-names></name>, <etal/><article-title>A novel CpG island set identifies tissue-specific methylation at developmental gene loci</article-title>. <source>PLoS Biol</source>. <year>2008</year>;<volume>6</volume>(<issue>1</issue>):<fpage>e22</fpage>.<pub-id pub-id-type="pmid">18232738</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Figure 1.</label>
              <caption>
                <p id="P28">Effect of naltrexone (open symbols), relative to placebo (closed symbols), on percent heavy drinking days (PHDD) during the 16-week trial as a function of <italic toggle="yes">SLC6A3</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter methylation. <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">OPRM1</italic> methylation are median split into low and high groups for display purposes. Naltrexone, relative to placebo, reduced PHDD more in study months 2 and 3 among participants with lower <italic toggle="yes">SLC6A3</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter methylation, and in study month 3 among participants with higher <italic toggle="yes">SLC6A3</italic> promoter and lower <italic toggle="yes">OPRM1</italic> promoter methylation. Asterisks indicate time points at which the effect of naltrexone vs. placebo was significant. Figures are estimated marginal means (± standard errors) from the linear mixed model.</p>
              </caption>
              <graphic xlink:href="nihms-1730440-f0001" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Figure 2.</label>
              <caption>
                <p id="P29">Effect of naltrexone (open symbols), relative to placebo (closed symbols), on percent heavy drinking days (PHDD) during the 16-week trial as a function of <italic toggle="yes">COMT</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter methylation. <italic toggle="yes">COMT</italic> and <italic toggle="yes">OPRM1</italic> methylation are median split into low and high groups for display purposes. Naltrexone, relative to placebo, reduced PHDD more among participants with lower <italic toggle="yes">COMT</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter methylation. The asterisk indicates the effect of naltrexone vs. placebo was significant across all study months. Figures are estimated marginal means (± standard errors) from the linear mixed model.</p>
              </caption>
              <graphic xlink:href="nihms-1730440-f0002" position="float"/>
            </fig>
            <fig position="float" id="F3">
              <label>Figure 3.</label>
              <caption>
                <p id="P30">Effect of naltrexone (open symbols), relative to placebo (closed symbols), on percent heavy drinking days (PHDD) during the 16-week trial as a function of <italic toggle="yes">SLC6A3</italic> VNTR and <italic toggle="yes">OPRM1</italic> promoter methylation. <italic toggle="yes">SLC6A3</italic> and <italic toggle="yes">OPRM1</italic> methylation are median split into low and high groups for display purposes. Naltrexone, relative to placebo, reduced PHDD more among participants with lower <italic toggle="yes">SLC6A3</italic> VNTR and <italic toggle="yes">OPRM1</italic> promoter methylation. The asterisk indicates the effect of naltrexone vs. placebo was significant across all study months. Figures are estimated marginal means (± standard errors) from the linear mixed model.</p>
              </caption>
              <graphic xlink:href="nihms-1730440-f0003" position="float"/>
            </fig>
            <table-wrap position="float" id="T1">
              <label>Table 1.</label>
              <caption>
                <p id="P31">Demographic characteristics and baseline alcohol use.</p>
              </caption>
              <table frame="box" rules="all">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th colspan="2" align="center" valign="top" rowspan="1">Naltrexone (<italic toggle="yes">n</italic> = 73)</th>
                    <th colspan="2" align="center" valign="top" rowspan="1">Placebo (<italic toggle="yes">n</italic> = 72)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>No.</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>%</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>No.</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>%</bold>
                    </td>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Test for difference</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Demographics</bold>
                    </td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Sex, M</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">51</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">69.9</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">49</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">68.1</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.81</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Employed</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">56</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">76.7</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">57</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">79.2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.72</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Education ≤ 12 years</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">12</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">16.4</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">11</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">15.3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.85</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Current nicotine user</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">32</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">43.8</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">26</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">36.1</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.34</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Recent cocaine use</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">8</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">11.0</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">11</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">15.3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.44</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Current antidepressant use</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">21</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">28.8</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">27</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">37.5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.26</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Mean</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>SD</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Mean</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>SD</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Demographics</bold>
                    </td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Age, years</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">50.7</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">9.3</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">48.1</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">10.8</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.13</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Alcohol use</bold>
                    </td>
                    <td align="right" valign="top" rowspan="1" colspan="1"/>
                    <td align="right" valign="top" rowspan="1" colspan="1"/>
                    <td align="right" valign="top" rowspan="1" colspan="1"/>
                    <td align="right" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Drinks per drinking day</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">11.9</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">5.2</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">10.5</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">4.3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.11</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Drinks per day</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">10.3</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">5.3</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">9.0</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">4.5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.08</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Heavy drinking days (%)</bold></td>
                    <td align="right" valign="top" rowspan="1" colspan="1">79.7</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">21.5</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">80.2</td>
                    <td align="right" valign="top" rowspan="1" colspan="1">22.9</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.89</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> <bold>Days from last drink to randomization</bold></td>
                    <td align="right" valign="middle" rowspan="1" colspan="1">6.6</td>
                    <td align="right" valign="middle" rowspan="1" colspan="1">4.1</td>
                    <td align="right" valign="middle" rowspan="1" colspan="1">7.3</td>
                    <td align="right" valign="middle" rowspan="1" colspan="1">4.7</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.33</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <p id="P32"><italic toggle="yes">p</italic> values indicate significance of χ<sup>2</sup> and <italic toggle="yes">t</italic> tests for differences between naltrexone and placebo groups.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T2">
              <label>Table 2.</label>
              <caption>
                <p id="P33">Fixed effects tests from models testing interactions between <italic toggle="yes">OPRM1</italic>, <italic toggle="yes">SLC6A3</italic>, and <italic toggle="yes">COMT</italic> methylation, medication group, and time in study on percent heavy drinking days.</p>
              </caption>
              <table frame="below" rules="none">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="bottom" rowspan="1" colspan="1">Model term</th>
                    <th align="left" valign="bottom" rowspan="1" colspan="1">df</th>
                    <th align="left" valign="bottom" rowspan="1" colspan="1">
                      <italic toggle="yes">F</italic>
                    </th>
                    <th align="left" valign="bottom" rowspan="1" colspan="1">
                      <italic toggle="yes">p</italic>
                    </th>
                  </tr>
                  <tr>
                    <th colspan="4" align="left" valign="bottom" rowspan="1">
                      <hr/>
                    </th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="2" align="left" valign="bottom" rowspan="1">
                      <bold><italic toggle="yes">Model 1: SLC6A3</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter methylation</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">SLC6A3</italic> promoter X group</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1, 150.74</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.35</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.56</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">OPRM1</italic> promoter X group</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1, 148.75</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.35</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.55</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">SLC6A3</italic> promoter X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 371.40</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4.48</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.004</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">OPRM1</italic> promoter X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 370.65</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4.14</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.007</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">SLC6A3</italic> promoter X <italic toggle="yes">OPRM1</italic> promoter X group</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1, 149.22</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.33</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.57</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <bold><italic toggle="yes">SLC6A3</italic> promoter X <italic toggle="yes">OPRM1</italic> promoter X group X time</bold></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>3, 370.82</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>4.17</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>0.006</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">
                      <bold><italic toggle="yes">Model2: COMT</italic> promoter and <italic toggle="yes">OPRM1</italic> promoter methylation</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">COMT</italic> promoter X group</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1, 148.10</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">7.18</td>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">0.008</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">OPRM1</italic> promoter X group</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1, 147.75</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8.07</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.005</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">COMT</italic> promoter X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 371.63</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2.45</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.063</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">OPRM1</italic> promoter X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 371.43</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2.38</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.070</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <bold><italic toggle="yes">COMT</italic> promoter X <italic toggle="yes">OPRM1</italic> promoter X group</bold></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>1, 147.85</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>8.13</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>0.005</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">COMT</italic> promoter X <italic toggle="yes">OPRM1</italic> promoter X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 371.50</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2.20</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.088</td>
                  </tr>
                  <tr>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">
                      <bold><italic toggle="yes">Model 3: SLC6A3</italic> VNTR and <italic toggle="yes">OPRM1</italic> promoter methylation</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">SLC6A3</italic> VNTR X group</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1, 156.63</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">9.52</td>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">0.002</td>
                  </tr>
                  <tr>
                    <td align="left" valign="bottom" rowspan="1" colspan="1"> <italic toggle="yes">OPRM1</italic> promoter X group</td>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">1, 153.86</td>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">8.87</td>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">0.003</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">SLC6A3</italic> VNTR X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 376.12</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2.17</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.092</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">OPRM1</italic> promoter X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 374.91</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2.07</td>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">0.10</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <bold><italic toggle="yes">SLC6A3</italic> VNTR X <italic toggle="yes">OPRM1</italic> promoter X group</bold></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>1, 154.33</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>8.38</bold>
                    </td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">
                      <bold>0.004</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> <italic toggle="yes">SLC6A3</italic> VNTR X <italic toggle="yes">OPRM1</italic> promoter X group X time</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3, 375.14</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1.97</td>
                    <td align="left" valign="bottom" rowspan="1" colspan="1">0.12</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN2">
                  <p id="P34">Figures are degrees of freedom (df), <italic toggle="yes">F</italic> statistics, and corresponding <italic toggle="yes">p</italic> values from linear mixed models that included all main effects and lower-level interactions and covaried age. For each model, the highest-level interaction that was significant at the Bonferroni-corrected threshold (<italic toggle="yes">p</italic> = 0.0167) is bolded.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
